Tech Company Financing Transactions

Aktis Oncology Funding Round

Aktis Oncology closed a $84 million Series A funding round on 8/26/2022. Investors included ArrowMark Partners, Bristol-Myers Squibb and Cowen Capital Partners.

Transaction Overview

Company Name
Aktis Oncology
Announced On
8/26/2022
Transaction Type
Venture Equity
Amount
$84,000,000
Round
Series A
Investors

ArrowMark Partners (Lead Investor)

Bristol-Myers Squibb (Lead Investor)

Cowen Capital Partners (Lead Investor)

EcoR1 Capital Management (Lead Investor)

Mirae Asset Venture Investment (Lead Investor)

MPM Capital (Lead Investor) (Todd Foley)

MRL Ventures (Lead Investor)

Octagon Investments Fund (Lead Investor)

Pappas Ventures (Lead Investor)

TCG Crossover (Lead Investor)

Timefolio Asset Management (Lead Investor)

Vida Ventures (Lead Investor)

Novartis

Proceeds Purpose
The company intends to use the funds to develop proprietary targeted alpha radiopharmaceutical pipeline for the treatment of highly prevalent cancers.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Princeton, NJ 08540
USA
Phone
Undisclosed
Website
www.aktisoncology.com
Email Address
[email protected]
Overview
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy.
Profile
Aktis Oncology LinkedIn Company Profile
Social Media
Aktis Oncology Company Twitter Account
Company News
Aktis Oncology News
Facebook
Aktis Oncology on Facebook
YouTube
Aktis Oncology on YouTube

Management Team

Title
Name
Email & Social
Chairman
Todd Foley
  Todd Foley LinkedIn Profile  Todd Foley Twitter Account  Todd Foley News  Todd Foley on Facebook
Chief Executive Officer
Matthew Roden
  Matthew Roden LinkedIn Profile  Matthew Roden Twitter Account  Matthew Roden News  Matthew Roden on Facebook

 

 

Browse more venture capital transactions:

Prev: 8/26/2022: Anaphite venture capital transaction
Next: 8/26/2022: Vestaron venture capital transaction

 

Share this article

 

News on VC Transactions

We report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.